Fibromyalgia Clinical Trial
Official title:
Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia: a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial
This was a double-blind, randomised, placebo-controlled, parallel-group, multicentre, multinational, Phase II study in 528 subjects with pain due to Fibromyalgia syndrome(FMS). Subjects were randomised in a 1:1:1:1 ratio to receive placebo, Eslicarbazepine acetate (ESL) 400 mg once daily (QD), ESL 800 mg QD or ESL 1200 mg QD. The study was carried out as follows.
This was a double-blind, randomised, placebo-controlled, parallel-group, multicentre,
multinational, Phase II study in 528 subjects with pain due to FMS. Subjects were randomised
in a 1:1:1:1 ratio to receive placebo, ESL 400 mg once daily (QD), ESL 800 mg QD or ESL 1200
mg QD. The study was carried out as follows:
Screening Visit (Visit [V] 1): After completing screening procedures at V1, eligible
subjects began the 2 week Baseline Period.
Baseline Period (2 weeks): Subjects discontinued taking prohibited medications on V1
(beginning of washout period). Subjects were tapered off of discontinued medications.
Washout was completed by Day -7 (7 days before V2). Subjects refrained from taking any pain
medications and other prohibited medications (except rescue medication) throughout the
study. During the Baseline Period, subjects used the subject diary to complete the diary
pain assessment on a 0-10 numeric pain rating scale (NPRS) and to record information on
rescue medication daily on awakening.
Titration Period (1 week): Upon completing the Baseline Period, subjects returned to the
study centre for V2 (Randomisation Visit, Day 1). At V2, subjects, who had completed at
least 4 subject diary pain assessments satisfactorily within the past 7 days, had an average
pain score that was ≥4 and ≤9 and continued to meet all study entry criteria, were randomly
assigned to 1 of the 4 treatment groups. During the 1-week Titration Period, subjects
randomised to the ESL 400 mg QD and the ESL 800 mg QD treatment groups received ESL 400 mg
QD; and subjects randomised to the ESL 1200 mg QD treatment group received ESL 600 mg QD;
subjects assigned to placebo treatment received placebo QD.
Maintenance Period (12 weeks): Starting at V3, subjects assigned to treatment with ESL
received their full dosage regimens QD; subjects assigned to placebo treatment received
placebo QD. During the Maintenance Period, subjects had visits every 4 weeks.
Follow-up Period (2 weeks): Approximately 2 weeks after taking the last dose of study
medication, subjects returned to the study centre for the Follow-up Visit and underwent the
end-of-study evaluations.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05659862 -
Digitally Assisted Behavioral Physical Activity Intervention in Fibromyalgia
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT03042728 -
Impact of Inclusion of a Therapy Dog Visit as Part of the Fibromyalgia Treatment Program
|
N/A | |
Recruiting |
NCT06097091 -
Effects and Mechanisms of Pain Neuroscience Education in Patients With Fibromyalgia
|
N/A | |
Recruiting |
NCT04554784 -
Effectiveness of Bowen Therapy for Pain Management in Patients With Fibromyalgia
|
N/A | |
Completed |
NCT03300635 -
Metabolism, Muscle Function and Psychological Factors in Fibromyalgia
|
N/A | |
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT03227952 -
Sensory Stimulation in Fibromyalgia
|
N/A | |
Completed |
NCT03166995 -
Postural Exercises in Women With Fibromyalgia
|
N/A | |
Recruiting |
NCT06237595 -
Vagus Nerve Stimulation in Fibromyalgia
|
N/A | |
Completed |
NCT01888640 -
Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation (FAST)
|
N/A | |
Completed |
NCT03641495 -
Pain Education and Therapeutic Exercise for Fibromyalgia
|
N/A | |
Recruiting |
NCT05581628 -
FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
|
||
Active, not recruiting |
NCT05128162 -
Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia
|
Phase 2 | |
Completed |
NCT04674878 -
Comparison of Muscle Energy Techniques and Breathing Exercises for Functional Improvement in Fibromyalgia
|
N/A | |
Active, not recruiting |
NCT04084795 -
Augmentation of EMDR With tDCS in the Treatment of Fibromyalgia
|
N/A | |
Completed |
NCT03129906 -
Impact of the Restriction of Sources of Gluten in Fibromyalgia Patients
|
N/A | |
Completed |
NCT05058911 -
Exposure-based Cognitive Behavior Therapy vs Traditional Cognitive Behavior Therapy for Fibromyalgia
|
N/A | |
Recruiting |
NCT04571528 -
Effectiveness of VIRTUAL FIBROWALK STUDY
|
N/A | |
Recruiting |
NCT04571853 -
New Educational Tool for FM
|
N/A |